O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

D M Verboom; M R J Varkila; B Morrow; T Davies; P Ibarra de Palacios; J Poolman; P W M Hermans; E G Dudley; E Roberts; O L Cremer; M J M Bonten

doi:10.1016/j.vaccine.2021.02.031

O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

D M Verboom, M R J Varkila, B Morrow, T Davies, P Ibarra de Palacios, J Poolman, P W M Hermans, E G Dudley, E Roberts, O L Cremer, M J M Bonten

Research output: Contribution to journal › Article › Academic › peer-review

4 Downloads (Pure)

Abstract

OBJECTIVES: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease.

METHODS: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing.

RESULTS: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37).

CONCLUSIONS: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.

Original language	English
Pages (from-to)	1670-1674
Number of pages	5
Journal	Vaccine
Volume	39
Issue number	12
Early online date	25 Feb 2021
DOIs	https://doi.org/10.1016/j.vaccine.2021.02.031
Publication status	Published - 19 Mar 2021

Keywords

Bloodstream infections
Escherichia coli
ExPEC
ICU
Vaccine

Access to Document

10.1016/j.vaccine.2021.02.031

1-s2.0-S0264410X21001985-mainFinal published version, 295 KBLicence: CC BY

Cite this

Verboom, D. M., Varkila, M. R. J., Morrow, B., Davies, T., Ibarra de Palacios, P., Poolman, J., Hermans, P. W. M., Dudley, E. G., Roberts, E., Cremer, O. L., & Bonten, M. J. M. (2021). O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands. Vaccine, 39(12), 1670-1674. https://doi.org/10.1016/j.vaccine.2021.02.031

@article{2bd8d30c21de41c2965db30c8b366822,

title = "O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands",

abstract = "OBJECTIVES: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease.METHODS: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing.RESULTS: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37).CONCLUSIONS: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.",

keywords = "Bloodstream infections, Escherichia coli, ExPEC, ICU, Vaccine",

author = "Verboom, {D M} and Varkila, {M R J} and B Morrow and T Davies and {Ibarra de Palacios}, P and J Poolman and Hermans, {P W M} and Dudley, {E G} and E Roberts and Cremer, {O L} and Bonten, {M J M}",

note = "Funding Information: D. Verboom and M. Bonten were funded by the Innovative Medicine Initiative (IMI), European Union{\textquoteright}s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies{\textquoteright} in-kind contribution (COMBACTE-CARE, grant agreement 115 620). Funding Information: We thank the members of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) consortium for their contribution to this research. D. Verboom and M. Bonten were funded by the Innovative Medicine Initiative (IMI), European Union's Seventh Framework Programme (FP7/2007?2013) and EFPIA companies? in-kind contribution (COMBACTE-CARE, grant agreement 115 620). Publisher Copyright: {\textcopyright} 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = mar,

day = "19",

doi = "10.1016/j.vaccine.2021.02.031",

language = "English",

volume = "39",

pages = "1670--1674",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "12",

}

TY - JOUR

T1 - O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

AU - Verboom, D M

AU - Varkila, M R J

AU - Morrow, B

AU - Davies, T

AU - Ibarra de Palacios, P

AU - Poolman, J

AU - Hermans, P W M

AU - Dudley, E G

AU - Roberts, E

AU - Cremer, O L

AU - Bonten, M J M

N1 - Funding Information: D. Verboom and M. Bonten were funded by the Innovative Medicine Initiative (IMI), European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in-kind contribution (COMBACTE-CARE, grant agreement 115 620). Funding Information: We thank the members of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) consortium for their contribution to this research. D. Verboom and M. Bonten were funded by the Innovative Medicine Initiative (IMI), European Union's Seventh Framework Programme (FP7/2007?2013) and EFPIA companies? in-kind contribution (COMBACTE-CARE, grant agreement 115 620). Publisher Copyright: © 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/3/19

Y1 - 2021/3/19

N2 - OBJECTIVES: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease.METHODS: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing.RESULTS: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37).CONCLUSIONS: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.

AB - OBJECTIVES: Invasive infections by extra-intestinal pathogenic Escherichia coli (ExPEC) strains are increasing. We determined O-serogroups of E. coli isolates from ICU patients having bloodstream infections (BSI) and the potential coverage of a 10-valent O-polysaccharide conjugate vaccine currently in development for the prevention of invasive ExPEC disease.METHODS: We studied E. coli BSI among patients admitted to a tertiary ICU in the Netherlands between April 2011 and November 2016. O-serogroups were determined in vitro by agglutination and whole genome sequencing.RESULTS: Among 714 ICU patients having BSI, 70 (10%) had an E. coli BSI. Among 68 (97%) isolates serogrouped, the most common serogroups were O25 (n = 11; 16%), O8 (n = 5; 7%), O2 (n = 4; 6%), O6 (n = 4; 6%), and O15 (n = 4; 6%). The theoretical coverage of a 10-valent ExPEC vaccine was 54% (n = 37).CONCLUSIONS: A multi-valent ExPEC O-polysaccharide conjugate vaccine in development could potentially aid in the prevention of E. coli BSI in Dutch ICU patients.

KW - Bloodstream infections

KW - Escherichia coli

KW - ExPEC

KW - ICU

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85101642793&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2021.02.031

DO - 10.1016/j.vaccine.2021.02.031

M3 - Article

C2 - 33642161

SN - 0264-410X

VL - 39

SP - 1670

EP - 1674

JO - Vaccine

JF - Vaccine

IS - 12

ER -

O-serotype distribution of Escherichia coli bloodstream infection isolates in critically ill patients in The Netherlands

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this